Evusheld, AstraZeneca’s dual-antibody injection, reduced the risk of COVID-19 by more than 76 percent at three months and by 83 percent at six months after immunization, new trial results show.
Source: Drug Industry Daily
Evusheld, AstraZeneca’s dual-antibody injection, reduced the risk of COVID-19 by more than 76 percent at three months and by 83 percent at six months after immunization, new trial results show.
Source: Drug Industry Daily